129 related articles for article (PubMed ID: 38726652)
1. Primary Human Papillomavirus Test Uptake and Cervical Cancer Screening Trends in the Midwest, United States.
Ehman KM; Jenkins GD; Grimm JA; Cammack TL; Samuelson BJ; Stoll RJ; Maxson JA; MacLaughlin KL
J Prim Care Community Health; 2024; 15():21501319241251934. PubMed ID: 38726652
[TBL] [Abstract][Full Text] [Related]
2. Assessment of US Preventive Services Task Force Guideline-Concordant Cervical Cancer Screening Rates and Reasons for Underscreening by Age, Race and Ethnicity, Sexual Orientation, Rurality, and Insurance, 2005 to 2019.
Suk R; Hong YR; Rajan SS; Xie Z; Zhu Y; Spencer JC
JAMA Netw Open; 2022 Jan; 5(1):e2143582. PubMed ID: 35040970
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Cervical Cancer Screening Among Infrequently Screened Women Completing Human Papillomavirus Self-Collection: My Body My Test-1.
Lea CS; Perez-Heydrich C; Des Marais AC; Richman AR; Barclay L; Brewer NT; Smith JS
J Womens Health (Larchmt); 2019 Aug; 28(8):1094-1104. PubMed ID: 30874477
[No Abstract] [Full Text] [Related]
4. Non-use and inadequate use of cervical cancer screening among a representative sample of women in the United States.
Narcisse MR; McElfish PA; Hallgren E; Pierre-Joseph N; Felix HC
Front Public Health; 2024; 12():1321253. PubMed ID: 38711762
[TBL] [Abstract][Full Text] [Related]
5. Persistent Disparities in Cervical Cancer Screening Uptake: Knowledge and Sociodemographic Determinants of Papanicolaou and Human Papillomavirus Testing Among Women in the United States.
Johnson NL; Head KJ; Scott SF; Zimet GD
Public Health Rep; 2020; 135(4):483-491. PubMed ID: 32516053
[TBL] [Abstract][Full Text] [Related]
6. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
7. Differences in cervical cancer screening and follow-up for black and white women in the United States.
Ford S; Tarraf W; Williams KP; Roman LA; Leach R
Gynecol Oncol; 2021 Feb; 160(2):369-374. PubMed ID: 33323276
[TBL] [Abstract][Full Text] [Related]
8. Acceptability and Feasibility of HPV Self-Sampling as an Alternative Primary Cervical Cancer Screening in Under-Screened Population Groups: A Cross-Sectional Study.
Wong EL; Cheung AW; Wong AY; Chan PK
Int J Environ Res Public Health; 2020 Aug; 17(17):. PubMed ID: 32867315
[No Abstract] [Full Text] [Related]
9. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.
Castanon A; Landy R; Pesola F; Windridge P; Sasieni P
Lancet Public Health; 2018 Jan; 3(1):e34-e43. PubMed ID: 29307386
[TBL] [Abstract][Full Text] [Related]
10. Age-specific effectiveness of primary human papillomavirus screening versus cytology in a cervical cancer screening program: a nationwide cross-sectional study.
Bao H; Ma L; Zhao Y; Song B; Di J; Wang L; Gao Y; Ren W; Wang S; Wu J; Wang HJ
Cancer Commun (Lond); 2022 Mar; 42(3):191-204. PubMed ID: 35142100
[TBL] [Abstract][Full Text] [Related]
11. Effect of Mailed Human Papillomavirus Test Kits vs Usual Care Reminders on Cervical Cancer Screening Uptake, Precancer Detection, and Treatment: A Randomized Clinical Trial.
Winer RL; Lin J; Tiro JA; Miglioretti DL; Beatty T; Gao H; Kimbel K; Thayer C; Buist DSM
JAMA Netw Open; 2019 Nov; 2(11):e1914729. PubMed ID: 31693128
[TBL] [Abstract][Full Text] [Related]
12. Cervical cancer screening and subsequent procedures in women under the age of 25 years between 2007 and 2013 in France: a nationwide French healthcare database study.
Maura G; Chaignot C; Weill A; Alla F; Heard I
Eur J Cancer Prev; 2018 Sep; 27(5):479-485. PubMed ID: 28368950
[TBL] [Abstract][Full Text] [Related]
13. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania.
Şuteu O; Blaga ML; Nygård M; Leinonen MK; Nicula F; Păiş R; Coza D; Cadariu PA; Melnic A; Andreassen T; Hashim D; Weiderpass E
Eur J Cancer Prev; 2020 Mar; 29(2):141-148. PubMed ID: 31033568
[TBL] [Abstract][Full Text] [Related]
15. Trends Over Time in Pap and Pap-HPV Cotesting for Cervical Cancer Screening.
MacLaughlin KL; Jacobson RM; Radecki Breitkopf C; Wilson PM; Jacobson DJ; Fan C; St Sauver JL; Rutten LJF
J Womens Health (Larchmt); 2019 Feb; 28(2):244-249. PubMed ID: 30614380
[TBL] [Abstract][Full Text] [Related]
16. Cancer Screening Patterns Among Current, Former, and Never Smokers in the United States, 2010-2015.
Sanford NN; Sher DJ; Butler S; Xu X; Ahn C; D'Amico AV; Rebbeck T; Aizer AA; Mahal BA
JAMA Netw Open; 2019 May; 2(5):e193759. PubMed ID: 31099863
[TBL] [Abstract][Full Text] [Related]
17. Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013-2019.
Qin J; Shahangian S; Saraiya M; Holt H; Gagnon M; Sawaya GF
Gynecol Oncol; 2021 Nov; 163(2):378-384. PubMed ID: 34507826
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and sociodemographic predictors of high-risk vaginal human papillomavirus infection: findings from a public cervical cancer screening registry.
Jailani AS; Balqis-Ali NZ; Tang KF; Fun WH; Samad SA; Jahaya R; Subakir NN; Ismail R; Said ZM; Sararaks S
BMC Public Health; 2023 Nov; 23(1):2243. PubMed ID: 37964260
[TBL] [Abstract][Full Text] [Related]
19. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
[TBL] [Abstract][Full Text] [Related]
20. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
